SRRKSRRKHealthcare · Biotechnology

SRRK Stock Forecast: Scholar Rock Holding Corp. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$45
+1.21% on the day

The 18 Wall Street analysts covering Scholar Rock Holding Corp. hold a median 12-month price target of $72 — +58.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 16 Nov 2026 — in the lower half.

Market cap
$5.3B
Ticker Nerd rank
47/ 100
Median analyst target
$72
Analysts covering
18
Revenue$0.0
Operating income−$108.9M
Net income−$109.9M
Free cash flow−$70.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.1%
1M
+13.0%
YTD
+2.3%
1Y
+23.6%
From 52W high
−24.9%
From 52W low
+23.6%
$36
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRRK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scholar Rock Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
47/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Momentum
76
Value
75
Volatility
74
Revisions
59
Growth
43
Quality
25
Size
22
Issuance
7

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SRRK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRRK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26SRRKHigh $84Median $72Low $58

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
16 Buy2 Hold0 Sell
Low $58Median $72High $84

The green dot is the last close — the median target sits +58.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
12 Nov 2026Wolfe ResearchDowngradePeer Perform—
24 Sept 2026Truist SecuritiesMaintainsBuy$76 → $77
24 Sept 2026Truist SecuritiesMaintainsBuy—
21 Sept 2026JP MorganMaintainsOverweight$63 → $70
21 Sept 2026JP MorganMaintainsOverweight—
15 Sept 2026BarclaysDowngradeEqual-Weight—
15 Sept 2026BarclaysDowngradeEqual-Weight$55 → $58
15 Sept 2026Evercore ISI GroupMaintainsOutperform—
15 Sept 2026Evercore ISI GroupMaintainsOutperform$65 → $72
15 Sept 2026HC Wainwright & Co.MaintainsBuy—
15 Sept 2026HC Wainwright & Co.MaintainsBuy$65 → $70
15 Sept 2026JefferiesMaintainsBuy—
15 Sept 2026JefferiesMaintainsBuy$57 → $65
15 Sept 2026Piper SandlerMaintainsOverweight—
15 Sept 2026Piper SandlerMaintainsOverweight$60 → $75
15 Sept 2026WedbushMaintainsOutperform—
15 Sept 2026WedbushMaintainsOutperform$64 → $70
14 Sept 2026BMO CapitalMaintainsOutperform—
14 Sept 2026BMO CapitalMaintainsOutperform$76 → $84
14 Sept 2026CitigroupMaintainsBuy$60 → $74

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SRRK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SRRK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Scholar Rock Holding Corp. returned +23.6% against +11.2% for the S&P 500, dividends included.

SRRK vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26SRRKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRRK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
6
Fundamentals

Scholar Rock Holding Corp. (SRRK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.1×

Cheaper than 95% of US stocks

Price / sales
9247.7×

Cheaper than 1% of US stocks

Price / book
31.2×

Cheaper than 3% of US stocks

EV / EBITDA
−12.4×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−71732.3%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−200.0%

Higher than 7% of US stocks

Return on assets
−59.6%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scholar Rock Holding Corp. (SRRK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scholar Rock Holding Corp. has a market value of $5.3B and an enterprise value of $5.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$408.6M.

  • Diluted earnings per share, trailing twelve months: −$3.45.

  • Free cash flow in the twelve months to 30 June 2026: −$297.0M.

  • Shares outstanding: 121.6M.

  • Trailing P/E: −13.1×; forward P/E: −17.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Scholar Rock Holding Corp. employs 289 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

SRRK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRRKScholar Rock Holding Corp.$5.3B47
MANEVeradermics, Inc.$5.3B5
ERASErasca, Inc.$5.2B48
PTCTPTC Therapeutics, Inc.$5.1B64
CAICaris Life Sciences, Inc.$5.9B25
MIRMMirum Pharmaceuticals, Inc.$5.9B56
DNTHDianthus Therapeutics, Inc.$4.9B77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scholar Rock Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRRK news & analysis

Scholar Rock to Present at Upcoming Investor Conferences

Business Wire · 17 Nov 2026neutral

Scholar Rock announced that its management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference at 8:45 a.m. ET on Tuesday, December 1, 2026.

Why it matters — The conference appearance provides SRRK watchers with a scheduled opportunity to hear from company management.

Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript

Seeking Alpha · 16 Nov 2026neutral

Scholar Rock CEO and Chairman David Hallal participated in a presentation at the UBS Global Biopharma Conference on November 16, 2026. The excerpt includes the session introduction by UBS analyst Michael Yee.

Why it matters — The transcript documents the company’s participation in an investor conference, though the excerpt does not provide substantive company updates.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 13 Nov 2026neutral

Scholar Rock granted inducement equity awards covering 39,587 shares to six newly hired employees. The awards comprise options for 11,349 shares and restricted stock units for 28,238 shares.

Why it matters — SRRK watchers may note the share-based compensation granted to new hires under Nasdaq Listing Rule 5635(c)(4).

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

MarketBeat · 10 Nov 2026negative

Scholar Rock reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment, ISEMBYLD. Executives said insurance and reimbursement hurdles are likely to delay most enrolled patients’ first infusions until 2027.

Why it matters — The update highlights early product revenue alongside a lengthy expected wait for most enrolled patients to begin treatment.

Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript

Seeking Alpha · 10 Nov 2026neutral

The provided text identifies a Seeking Alpha transcript of Scholar Rock Holding Corporation’s Q3 2026 earnings call but gives no details from the call.

Why it matters — SRRK watchers can note that a Q3 2026 earnings-call transcript is the subject, though the excerpt contains no company updates to assess.

FAQ

Frequently asked questions about SRRK stock

What is the SRRK stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Scholar Rock Holding Corp. have a median 12-month price target of $72, with estimates ranging from $58 to $84. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRRK stock a buy right now?

Of the 18 analysts covering Scholar Rock Holding Corp., 16 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scholar Rock Holding Corp. 47 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRRK?

As at 16 Nov 2026, Scholar Rock Holding Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will SRRK stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +58.6% from the last close, and Ticker Nerd's factor model ranks Scholar Rock Holding Corp. 47 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRRK stock forecast for 2030?

No analyst covering Scholar Rock Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRRK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $84 over the next 12 months.

How has SRRK stock performed over the past year?

Scholar Rock Holding Corp. returned +23.6% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scholar Rock Holding Corp. do?

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role.

What is the latest news on SRRK?

The most recent item we track (Business Wire, 17 Nov 2026): "Scholar Rock to Present at Upcoming Investor Conferences". Scholar Rock announced that its management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference at 8:45 a.m. ET on Tuesday, December 1, 2026.

Company

About Scholar Rock Holding Corp.

Scholar Rock Holding Corporation Common Stock represents an equity interest in Scholar Rock Holding Corporation, a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, with an emphasis on rare neuromuscular disorders such as spinal muscular atrophy (SMA). The company’s current pipeline is centered on apitegromab, its lead investigational therapy, alongside additional programs in neuromuscular and other severe disease areas where protein growth factor signaling plays a key role. Scholar Rock applies its myostatin biology platform to advance treatments intended to address significant unmet medical needs in patients across pediatric and adult populations. The company is headquartered in Cambridge, Massachusetts, and its common stock is used by investors to track the market’s view of its clinical development progress, regulatory milestones, and broader biopharmaceutical execution.

CEO Mr. David L. Hallal · 289 employees · United States · https://www.scholarrock.com